Nupathe Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2012 | $28 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| Aug 2011 | $1 M | No. 1 | Under $2 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Nupathe Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2012).
SEC Form D · Nov 2012
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2012
That is all the official record says: Nupathe Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
16 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Battelle Ventures, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| BioAdvance Ventures L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2010) | SEC Form 3 |
| Birchmere Ventures III LP | Venture capital | not stated | not stated | Held Series A and B preferred stock (Form 3, 2010) | SEC Form 3 |
| Birchmere Ventures III TSIB LP | Venture capital | not stated | not stated | Held Series A and B preferred stock (Form 3, 2010) | SEC Form 3 |
| BV3 LLC | Other | not stated | not stated | Held Series A and B preferred stock (Form 3, 2010) | SEC Form 3 |
| BV3 Management LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock (Form 3, 2010) | SEC Form 3 |
| BVP GP LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Ezra H. Felker | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2010) | SEC Form 3 |
| Innovation Valley Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Ivp GP, LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Jane H. Hollingsworth | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2010) | SEC Form 3 |
| Keith A. Goldan | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2010) | SEC Form 3 |
| Quaker BioVentures II LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Sabby Healthcare Volatility Master Fund, Ltd. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| Sabby Management, LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| Safeguard Scientifics Inc | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2010) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 20 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Armando Anido | Executive officer | Nov 2012 |
| Bart J. Dunn | Executive officer | Nov 2012 |
| Gerald W. McLaughlin | Executive officer | Nov 2012 |
| Keith A. Goldan | Executive officer | Nov 2012 |
| Michael F. Marino | Executive officer | Nov 2012 |
| Terri B. Sebree | Executive officer | Nov 2012 |
| Ezra H. Felker | Executive officer | Aug 2011 |
| Jane H. Hollingsworth | Executive officer | Aug 2011 |
| Armando Anido | Director | Nov 2012 |
| Brian J. Sisko | Director | Nov 2012 |
| James A. Datin | Director | Nov 2012 |
| Michael P. Cola | Director | Nov 2012 |
| Richard S. Kollender | Director | Nov 2012 |
| Robert P. Roche | Director | Nov 2012 |
| Wayne P. Yetter | Director | Nov 2012 |
| William J. Federici | Director | Nov 2012 |
| Gary J. Kurtzman | Director | Aug 2011 |
| Jane H. Hollingsworth | Director | Aug 2011 |
| Jeanne F. Cunicelli | Director | Aug 2011 |
| Michael F. Cola | Director | Aug 2011 |